---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-026322"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:06:19.291287+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OS Therapies reports FY2024 net operating loss of $10.9M; cash runway into 2026

## Summary
- Net operating loss $10.886M in 2024 vs $7.916M in 2023, driven by IPO costs.
- Net loss per share $0.88 on 12.38M shares vs $1.46 on 5.43M shares in 2023.
- Cash on hand expected to last into 2026 due to reduced burn rate starting Q2 2025.
- Full Phase 2b OST-HER2 data to be presented June 2025; BLA submission targeted for year-end 2025.
- Plans to divest anticipated Priority Review Voucher (PRV) from potential BLA approval.

## SEC filing metadata
- accession: 0001213900-25-026322
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/0001213900-25-026322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/ea0236436-8k_ostherapi.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-026322
- JSON: https://secwatch.observer/filing/0001213900-25-026322.json
- Plain text: https://secwatch.observer/filing/0001213900-25-026322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.